Citadel Group — Major Shareholding Notification 2023

Jun 13, 2023

National Storage Mechanism | Additional information

RNS Number : 5863C

Citadel Group

13 June 2023

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.             KEY INFORMATION

(a)   Full name of discloser	Citadel Group
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree	HORIZON THERAPEUTICS PLC
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)	N/A
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure	12 June 2023
(f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

2.             INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security (Note 3)	Common Stock ISIN IE00BQPVQZ61
	Interests		Short positions
Number	%	Number	%
(1)   Relevant securities owned and/or controlled	4,846,245	2.11	873	0.00
(2)   Cash-settled derivatives	0	0.00	0	0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell	804,400	0.35	1,542,500	0.67
Total	5,650,645	2.47	1,543,373	0.67

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)           Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit (Note 5)
Common	Buy Transaction	16,836	99.5928 USD
Common	Buy Transaction	3,233	99.5995 USD
Common	Buy Transaction	78	99.6035 USD
Common	Buy Transaction	201	99.6042 USD
Common	Buy Transaction	41	99.6046 USD
Common	Buy Transaction	269	99.6234 USD
Common	Buy Transaction	99	99.6248 USD
Common	Buy Transaction	58	99.6255 USD
Common	Buy Transaction	100	99.6300 USD
Common	Buy Transaction	11	99.6600 USD
Common	Buy Transaction	159	99.6607 USD
Common	Buy Transaction	775	99.6617 USD
Common	Buy Transaction	295	99.6623 USD
Common	Buy Transaction	72	99.6799 USD
Common	Buy Transaction	352	99.6821 USD
Common	Buy Transaction	139	99.6835 USD
Common	Buy Transaction	261	99.6900 USD
Common	Buy Transaction	2,490	99.6911 USD
Common	Buy Transaction	6,585	99.6921 USD
Common	Buy Transaction	1,380	99.6930 USD
Common	Buy Transaction	40	99.6965 USD
Common	Buy Transaction	515	99.6996 USD
Common	Buy Transaction	326	99.7004 USD
Common	Buy Transaction	1,326	99.7009 USD
Common	Buy Transaction	1,545	99.7018 USD
Common	Buy Transaction	249	99.7025 USD
Common	Buy Transaction	271	99.7028 USD
Common	Buy Transaction	577	99.7035 USD
Common	Buy Transaction	1,168	99.7042 USD
Common	Buy Transaction	440	99.7052 USD
Common	Buy Transaction	654	99.7303 USD
Common	Buy Transaction	200	99.7350 USD
Common	Buy Transaction	100	99.7600 USD
Common	Buy Transaction	3,342	99.7745 USD
Common	Buy Transaction	669	99.7745 USD
Common	Buy Transaction	1,290	99.7748 USD
Common	Buy Transaction	1,300	99.7883 USD
Common	Buy Transaction	16,338	99.7936 USD
Common	Buy Transaction	208	99.7966 USD
Common	Buy Transaction	1,019	99.7972 USD
Common	Buy Transaction	15,000	99.7973 USD
Common	Buy Transaction	399	99.7979 USD
Common	Buy Transaction	200	99.8275 USD
Common	Buy Transaction	5	99.8700 USD
Common	Buy Transaction	1,500	99.8713 USD
Common	Buy Transaction	84	99.8905 USD
Common	Buy Transaction	221	99.8914 USD
Common	Buy Transaction	918	99.8926 USD
Common	Buy Transaction	45	99.8933 USD
Common	Sell Transaction	907	99.6673 USD

Ap29

(b)           Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position	Number of reference securities (Note 6)	Price per unit (Note 5)

(c)           Stock-settled derivative transactions (including options)

(i)            Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates (Note 6)	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)           Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit (Note 5)

(d)           Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant security	Nature of dealing e.g. subscription, conversion, exercise	Details	Price per unit (if applicable) (Note 5)

Ap30

4.             OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None

(b)           Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None

(c)           Attachments

Is a Supplemental Form 8 attached?	YES

Date of disclosure	13 June 2023
Contact name	Paula Sharp
Telephone number	020 7645 9700

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1.             KEY INFORMATION

Full name of person making disclosure:	Citadel Group
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	HORIZON THERAPEUTICS PLC

2.             STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
Common	Call Option	Purchased	50,000	115.0 USD	American	18/08/2023
Common	Put Option	Purchased	-62,500	70.0 USD	American	19/01/2024
Common	Call Option	Purchased	11,100	105.0 USD	American	18/08/2023
Common	Put Option	Purchased	-74,700	100.0 USD	American	18/08/2023
Common	Put Option	Purchased	-42,400	85.0 USD	American	18/08/2023
Common	Put Option	Purchased	-280,000	80.0 USD	American	15/12/2023
Common	Put Option	Purchased	-15,000	90.0 USD	American	18/08/2023
Common	Put Option	Purchased	-220,100	95.0 USD	American	18/08/2023
Common	Put Option	Purchased	-18,700	80.0 USD	American	18/08/2023
Common	Put Option	Sold	280,000	90.0 USD	American	21/07/2023
Common	Call Option	Sold	-2,000	115.0 USD	American	16/06/2023
Common	Call Option	Sold	-100	110.0 USD	American	16/06/2023
Common	Put Option	Sold	300,000	85.0 USD	American	16/06/2023
Common	Call Option	Sold	-500,000	105.0 USD	American	16/06/2023
Common	Call Option	Sold	-12,000	100.0 USD	American	21/07/2023
Common	Put Option	Sold	100	75.0 USD	American	16/06/2023
Common	Put Option	Sold	10,000	100.0 USD	American	16/06/2023
Common	Put Option	Sold	32,800	55.0 USD	American	17/11/2023
Common	Put Option	Sold	62,500	90.0 USD	American	19/01/2024
Common	Put Option	Sold	4,400	60.0 USD	American	18/08/2023
Common	Put Option	Sold	100	65.0 USD	American	21/07/2023
Common	Call Option	Sold	-5,000	120.0 USD	American	18/08/2023
Common	Call Option	Sold	-10,000	101.0 USD	American	16/06/2023
Common	Put Option	Sold	700	50.0 USD	American	19/01/2024
Common	Call Option	Sold	-300,000	100.0 USD	American	16/06/2023
Common	Put Option	Sold	700	60.0 USD	American	17/11/2023
Common	Put Option	Sold	52,000	55.0 USD	American	15/09/2023

3.             AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4.             RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPGPUWPQUPWGPW